Novartis announced today that Cosentyx® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles of

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In